ADVERTISEMENT

Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

Meeting Abstract: 2014 Gastrointestinal Cancers Symposium

FREE ACCESS Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract January 20, 2014

Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).

Authors: Marlo A. Blazer, Christina Sing-Ying Wu, Richard M. Goldberg, Gary S. Phillips, Carl Richard Schmidt, Peter Muscarella, Samer S El-Dika, … SHOW ALL …, and Tanios S. Bekaii-Saab | AUTHORS INFO & AFFILIATIONS

Publication: Journal of Clinical Oncology Volume 32, Number 3_suppl https://doi.org/10.1200/jco.2014.32.3_suppl.275

3

Abstract

275

Background: FOLFIRINOX exhibits a meaningful improvement in outcome measures in metastatic pancreatic cancer, making it an interesting regimen for BRPC and LAURPC. However, its use remains prohibitive due to toxicity. In this study, we examine the outcomes of mFOLFIRINOX as a neoadjuvant strategy for patients with BRPC and LAURPC. **Methods:** This is a retrospective analysis of a prospectively maintained database of patients who received mFOLFIRINOX for BRPC or LAURPC at Ohio State University. mFOLFIRINOX is as follows: irinotecan at 165 mg/m^2; oxaliplatin at 85 mg/m^2; 5-fluorouracil (5FU) at 2,400 mg/m^2 over 46 hours and pegfilgrastim on day 4 of each 2-week cycle. Cases were thoroughly reviewed by a multidisciplinary team prior to initiation of therapy and at each restaging scan. The primary outcomes of this analysis were resection rate and grade 3/4 (G3/4) toxicities. **Results:** Since 1/1/2011, 43 patients (20 BRPC; 23 LAURPC) have received mFOLFIRINOX. Patients received gemcitabine-based chemoradiation (36 Gy in 15 fractions) only if their best response was stable disease after 4 months of mFOLFIRINOX. At the time of this abstract, 39 patients are evaluable for primary outcome. Overall resection rate was 53.8% including 45% of patients with initially unresectable disease. R0 resection was achieved in 85.7% of the surgeries. See table for more results. The rate of G3/4 toxicity was remarkably low with no episodes of febrile neutropenia, G3/4 neutropenia or thrombocytopenia. Toxicities lead to dose reductions in 46% of patients. **Conclusions:** Neoadjuvant mFOLFIRINOX is an effective, well-tolerated regimen as part of an integrated, multimodality strategy in BRPC and LAURPC leading to high resection rates and high R0 resection frequency.

All patients (n = 43)	
Age, median (yo)	65 (range: 40-81)

All patients (n = 43)		
ECOG 0-1 (%)	100%	
BRPC, n	20	
LAURPC, n	23	
Median # of cycles:	4 (range: 1-10)	
Evaluable patients (n = 39)		
Overall resection rate	53.8%	
Median PFS		
Resected	18.4 months	
Unresected	9.2 months (log-rank p-value <0.001)	
	BRPC (n=19)	**LAURPC (n=20)**
Received chemo/XRT, n (%)	10 (52.6%)	13 (65%)
Achieved resection, n (%)		
Overall	12 (63.2%)	9 (45%)
R0	10 (52.6%)	8 (40%)

COLLAPSE

This is an ASCO Meeting Abstract from the 2014 Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

New Journal: *JCO Oncology Advances*

EDITORIALS | SEPTEMBER 12, 2024

Advancing Oncology Through Broad Access and Inclusive Science

ORIGINAL REPORTS | SEPTEMBER 12, 2024

Examining Racial Disparities in the Association Between Food Swamps and Early-Onset Colorectal Cancer Mortality

ORIGINAL REPORTS | SEPTEMBER 12, 2024

Clinical Outcomes and Efficacy of HER2-Targeted Therapy in Breast Cancer with Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry

COMMENTARIES | SEPTEMBER 12, 2024

Small Cell Lung Cancer: New Hope, New Challenges

Recommended Articles

GASTROINTESTINAL (NONCOLORECTAL) CANCER | MAY 20, 2015

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.

PANCREATIC CANCER | FEB 04, 2020

Efficacy and safety of mFOLFIRINOX in patients with borderline resectable and locally advanced unresectable pancreatic cancer: Intention-to-treat population analysis.

PANCREATIC CANCER | FEB 04, 2020

The surgical outcomes of borderline resectable or locally advanced pancreatic cancer.

CANCERS OF THE PANCREAS, SMALL BOWEL, AND HEPATOBILIARY TRACT | FEB 01, 2016

Is neoadjuvant chemoradiation important in borderline resectable pancreatic cancer (BRPC)? Clinical and surgical outcomes associated with preoperative FOLFIRINOX alone in BRPC.

CANCERS OF THE PANCREAS, SMALL BOWEL, AND HEPATOBILIARY TRACT | JAN 20, 2014

Surgical strategy for borderline resectable pancreatic body cancer.

JOURNALS
Journal of Clinical Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer Informatics
JCO Precision Oncology
JCO Oncology Advances

PUBLICATIONS
ASCO Educational Book
ASCO Daily News
ASCO Connection
The ASCO Post
ASCO Podcasts

CONTENT
Journal Podcasts
Topics
Meeting Abstracts
ASCO Guidelines

INFORMATION
Author Center
Subscriber Center
Permissions
Reprints
Advertise
E-Alerts
View My Profile
About ASCO Journals

FOLLOW US
JCO_ASCO
JCOOP_ASCO
JCOGO_ASCO
JCOPO_ASCO
JCOCCI_ASCO

ASCO
About ASCO
Press Center
Meetings & Education
Contact Us

ASCO WEBSITES
asco.org
ASCO Career Center
Conquer Cancer

American Society of Clinical Oncology
2318 Mill Road, Suite 800, Alexandria, VA 22314
© 2025 American Society of Clinical Oncology

Site Map | Terms of Use | Privacy Policy | Cookies